1. Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System
- Author
-
Oddmund Nordgård, Bjørnar Gilje, Liv Cecilie Vestrheim Thomsen, Bjørn Henning Grønberg, Kjersti Tjensvoll, Reidun K. Kopperud, Karl-Henning Kalland, Rakel Brendsdal Forthun, Bjørn Tore Gjertsen, Morten Lapin, and Randi Hovland
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,biopsi ,Review ,circulating tumor cells ,lcsh:RC254-282 ,Metastasis ,liquid biopsies ,03 medical and health sciences ,0302 clinical medicine ,Circulating tumor cell ,Internal medicine ,onkologi ,cancer ,Medicine ,Clinical significance ,sirkulerende kreftceller ,Liquid biopsy ,Lung cancer ,circulating tumor DNA ,business.industry ,Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762 [VDP] ,Cancer ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,030104 developmental biology ,Circulating tumor DNA ,030220 oncology & carcinogenesis ,business ,Healthcare system - Abstract
Simple Summary We here review liquid biopsy methods and their use in the diagnostics and treatment of patients with solid cancers. More specifically, circulating tumor DNA, circulating tumor cells, and their current and future clinical applications are considered. Important factors for further integration of liquid biopsy methods in clinical practice are discussed, with a special focus on a Nordic Healthcare system. Abstract Liquid biopsies have emerged as a potential new diagnostic tool, providing detailed information relevant for characterization and treatment of solid cancers. We here present an overview of current evidence supporting the clinical relevance of liquid biopsy assessments. We also discuss the implementation of liquid biopsies in clinical studies and their current and future clinical role, with a special reference to the Nordic healthcare systems. Our considerations are restricted to the most established liquid biopsy specimens: circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Both ctDNA and CTCs have been used for prognostic stratification, treatment choices, and treatment monitoring in solid cancers. Several recent publications also support the role of ctDNA in early cancer detection. ctDNA seems to provide more robust clinically relevant information in general, whereas CTCs have the potential to answer more basic questions related to cancer biology and metastasis. Epidermal growth factor receptor-directed treatment of non-small-cell lung cancer represents a clinical setting where ctDNA already has entered the clinic. The role of liquid biopsies in treatment decisions, standardization of methods, diagnostic performance and the need for further research, as well as cost and regulatory issues were identified as factors that influence further integration in the clinic. In conclusion, substantial evidence supports the clinical utility of liquid biopsies in cancer diagnostics, but further research is still required for a more general application in clinical practice.
- Published
- 2021